FDA OKs emergency use of Hologic high-throughput COVID-19 molecular test

Hologic (NASDAQ:HOLX) announces emergency use authorization in the U.S. for its Panther Fusion SARS-CoV-2 molecular assay for use in testing asymptomatic people for COVID-19 infection (in other words, the high-throughput test can be used to screen people who may have been exposed to an infected person).

The automated Panther Fusion system can generate initial results in ~three hours and more than 1,000 coronavirus tests in 24 hours.

https://seekingalpha.com/news/3617605-fda-oks-emergency-use-of-hologic-high-throughput-covidminus-19-molecular-test